Protalix BioTherapeutics (PLX) Gross Margin (2010 - 2026)
Protalix BioTherapeutics (PLX) posted quarterly Gross Margin of 87.77% for Q1 2026, up 6866.0% year-over-year from 1.26% in Q1 2025, and up 77.8% quarter-over-quarter from 49.36% in Q4 2025.
Protalix BioTherapeutics (PLX) Gross Margin (2010 - 2026) Analysis & Trends
Protalix BioTherapeutics' Gross Margin history runs 17 years deep, the most recent figure standing at 87.77% for Q1 2026.
- In Q1 2026, Gross Margin rose 6866.0% year-over-year to 87.77%; the TTM figure through Mar 2026 stood at 69.97% (up 1999.0% YoY), while the FY2025 annual figure was 48.82%, down 564.0% from the prior year.
- Gross Margin for Q1 2026 stood at 87.77%, up from 49.36% in the prior quarter.
- The five-year high for Gross Margin was 87.77% in Q1 2026, with the low at 15.54% in Q4 2023.
- The 5-year median for Gross Margin is 53.37% (2024), against an average of 54.19%.
- The sharpest annual moves came in 2023 and 2026: Gross Margin plunged 5664 bps in 2023, then soared 6866 bps in 2026.
- Protalix BioTherapeutics' Gross Margin stood at 72.18% in 2022, then slumped by 78 bps to 15.54% in 2023, then jumped by 406 bps to 78.67% in 2024, then plunged by 37 bps to 49.36% in 2025, then jumped by 78 bps to 87.77% in 2026.
- Business Quant data shows PLX's Gross Margin at 87.77% in Q1 2026, 49.36% in Q4 2025, and 53.37% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | 35.86% |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 89.76% |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | 76.90% |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | 63.27% |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 84.20% |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | - |
| 10 | Protalix BioTherapeutics | 189.97 Mn | 149.31 Mn | 12.13 Mn | 60.99% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 60.99% |
| Mar 31, 2026 | 87.77% |
| Dec 31, 2025 | 49.36% |
| Sep 30, 2025 | 53.37% |
| Jun 30, 2025 | 62.51% |
| Mar 31, 2025 | 19.11% |
| Dec 31, 2024 | 78.67% |
| Sep 30, 2024 | 53.37% |
| Jun 30, 2024 | 29.82% |
| Mar 31, 2024 | 30.58% |
| Dec 31, 2023 | 15.54% |
| Sep 30, 2023 | 52.70% |
| Jun 30, 2023 | 82.47% |
| Mar 31, 2023 | 67.82% |
| Dec 31, 2022 | 72.18% |
| Sep 30, 2022 | 50.12% |
| Jun 30, 2022 | 53.31% |
| Mar 31, 2022 | 62.49% |
| Dec 31, 2021 | 63.18% |
| Sep 30, 2021 | 69.28% |